December 22, 2016 / 5:41 PM / 7 months ago

BRIEF-Vifor Pharma & Chemocentryx expands alliance to include CCX140 to treat renal diseases

1 Min Read

Dec 22 (Reuters) - Chemocentryx Inc:

* Vifor Pharma and Chemocentryx announce expansion of kidney health alliance to include CCX140 to treat renal diseases

* Chemocentryx to receive upfront cash commitment of USD 50 million plus potential milestones and royalties

* Will be responsible for clinical development of CCX140 in rare renal diseases, while sharing cost of such development with Vifor Pharma

* Vifor pharma receives option to develop, commercialize ccx140 in chronic kidney disease with U.S. Co-Promotion rights retained by Co

* Co will be eligible to receive tiered double-digit royalties on net sales of CCX140 in licensed territories

* Co will be eligible to receive additional payments upon achievement of certain development, regulatory and sales-based milestones

* Co Retains marketing rights for rare renal disease in U.S. and China, while Vifor Pharma has commercialization rights in rest of world Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below